Threshold NeuroDiagnostics makes the Medusa Electrode, an FDA-registered Class II device that adapts neuromodulation leads to universal EEG connectors so clinicians and researchers can record neural signals with standard neurophysiology equipment. Founded around the hands-on expertise of Geoffrey Allott, the company draws on more than 16 years connecting to neuromodulation electrodes and experience with over 400 human-subject procedures. Its work also supports research into brain and spinal stimulation, including biomarker access and neural-network mapping.
FDA-registered Class II (exempt) medical product
Registration
FDACLASSII
Quality certification
Neurosteer IncFounded in 2015 by Tel Aviv University professor Nathan Intrator, Neurosteer develops a wearable, medical-grade brain-activity interpretation platform built around a pocket-sized, single-channel EEG monitor. Its wireless forehead sensor and cloud-based analysis provide real-time brain metrics for clinical assessment, continuous monitoring and research, and the device has FDA Class II clearance. Neurosteer’s teams work across New York, California and Israel, drawing on expertise in neuroscience and signal processing.NEW YORK, NY
Precision Neuroscopics, IncBorn from a Carnegie Mellon University research effort in 2015, Pittsburgh-based Precision Neuroscopics develops EEG technologies for brain monitoring and diagnosis. Its work is especially distinctive for Sevo, an EEG adapter designed for coarse and curly hair, alongside algorithms that detect otherwise hidden electrical changes after brain injury. The company’s team brings together neuroscientists, physicians, engineers, and entrepreneurs around its goal of making EEG more accessible.334510PITTSBURGH, PA
BrainScope Company, IncFounded in 2006, BrainScope develops medical neurotechnology that converts brain electrical activity (EEG) into objective, point-of-care assessments for brain health. Its FDA-cleared system was the first AI/machine-learning medical device cleared in neurology and is used to assess head injuries for the likelihood of brain bleeds and concussion without radiation. The company is now extending its EEG-based platform into digital biomarkers for conditions including stroke and cognitive decline.ROCKVILLE, MD
Bio-Signal Group CorpFounded in 2002 by NYU neuroscientist André Fenton, Bio-Signal Group Corp. develops portable neurodiagnostic equipment and software that bring clinical-grade EEG testing beyond the traditional hospital lab. Its FDA-cleared microEEG® system can be set up in about five minutes without a specialized EEG technician, with cloud-based interpretation enabling board-certified neurologists to read studies remotely in less than an hour. The company’s work serves settings ranging from emergency departments and physician practices to sports concussion management.BROOKLYN, NY